SRSD107
Phase 2Small molecule
SRSD107 is one of 45 small molecule programs targeting Peripheral Arterial Disease. It is currently in Phase 2.
1
Indications
3
Total Trials
2
Active Trials
44
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
101 competitors in Peripheral Arterial Disease
#DrugCompanyPhaseTrials
1Ozempic
Novo NordiskPhase 3
Foundayo
Eli LillyPhase 3
Viagra
VViatris Specialty LLC
Phase 3
Bystolic
VVitae Pharmaceuticals Inc., an Allergan affiliate
Phase 3
Singulair
OOrganon and Co
Phase 3
Omacor
AstraZenecaPhase 3
Ticlid
RochePhase 3
Savaysa
Daiichi SankyoPhase 2
Kuvan
BioMarin PharmaceuticalPhase 2
DLBS1033
DDexa Medica Group
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Phase 11 trial
Peripheral Arterial Disease1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SRSD107. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- SSirius Therapeutics Co., Ltd.